RT Journal Article
T1 Predictors of clinically significant quality of life impairment in Parkinson's disease.
A1 Santos García, Diego
A1 de Deus Fonticoba, Teresa
A1 Cores, Carlos
A1 Muñoz, Guillermo
A1 Paz González, Jose M
A1 Martínez Miró, Cristina
A1 Suárez, Ester
A1 Jesús, Silvia
A1 Aguilar, Miquel
A1 Pastor, Pau
A1 Planellas, Lluis
A1 Cosgaya, Marina
A1 García Caldentey, Juan
A1 Caballol, Nuria
A1 Legarda, Inés
A1 Hernández Vara, Jorge
A1 Cabo, Iria
A1 López Manzanares, Luis
A1 González Aramburu, Isabel
A1 Ávila Rivera, María A
A1 Catalán, Maria J
A1 Nogueira, Víctor
A1 Puente, Víctor
A1 Ruíz de Arcos, María
A1 Borrué, Carmen
A1 Solano Vila, Berta
A1 Álvarez Sauco, María
A1 Vela, Lydia
A1 Escalante, Sonia
A1 Cubo, Esther
A1 Carrillo Padilla, Francisco
A1 Martínez Castrillo, Juan C
A1 Sánchez Alonso, Pilar
A1 Alonso Losada, Maria G
A1 López Ariztegui, Nuria
A1 Gastón, Itziar
A1 Clavero, Pedro
A1 Kulisevsky, Jaime
A1 Blázquez Estrada, Marta
A1 Seijo, Manuel
A1 Rúiz Martínez, Javier
A1 Valero, Caridad
A1 Kurtis, Mónica
A1 de Fábregues, Oriol
A1 González Ardura, Jessica
A1 Ordás, Carlos
A1 López Díaz, Luis M
A1 McAfee, Darrian
A1 Martinez-Martin, Pablo
A1 Mir, Pablo
A1 COPPADIS Study Group, 
AB Quality of life (QOL) plays an important role in independent living in Parkinson's disease (PD) patients, being crucial to know what factors impact QoL throughout the course of the disease. Here we identified predictors of QoL impairment in PD patients from a Spanish cohort. PD patients recruited from 35 centers of Spain from the COPPADIS cohort from January 2016, to November 2017, were followed up during 2 years. Health-related QoL (HRQoL) and global QoL (GQoL) were assessed with the 39-item Parkinson's disease Questionnaire (PDQ-39) and the EUROHIS-QOL 8-item index (EUROHIS-QOL8), respectively, at baseline (V0) and at 24 months ± 1 month (V2). Clinically significant QoL impairment was defined as presenting an increase (PDQ-39SI) or decrement (EUROHIS-QOL8) at V2 ≥ 10% of the score at baseline (V0). A comparison with a control group was conducted for GQoL. GQoL did not change significantly in PD patients (N = 507; p = 0.686) or in the control group (N = 119; p = 0.192). The mean PDQ-39SI was significantly increased in PD patients (62.7 ± 8.5 years old; 58.8% males; N = 500) by 21.6% (from 16.7 ± 13 to 20.3 ± 16.4; p 
SN 2373-8057
YR 2021
FD 2021-12-16
LK https://hdl.handle.net/10668/27941
UL https://hdl.handle.net/10668/27941
LA en
DS RISalud
RD Apr 12, 2025